What's Happening?
Pfizer and BioNTech have decided to halt enrollment in a large U.S.-based trial of their updated COVID-19 vaccine due to slow recruitment of participants. The trial aimed to enroll 25,000 to 30,000 healthy adults aged 50 to 64, but enrollment was closed
on March 6 after reviewing epidemiological trends. The companies informed trial investigators that surveillance for COVID-19 illness would cease after April 3. The slow enrollment is attributed to the difficulty in recruiting this age group, especially since individuals with chronic conditions like hypertension or diabetes were excluded from the study.
Why It's Important?
The halt in the trial could impact the availability of post-marketing data necessary for regulatory decisions regarding the vaccine's use in the specified age group. This development highlights challenges in clinical trial recruitment, particularly for COVID-19 vaccines, which are crucial for public health strategies. The situation also reflects broader issues in the U.S. vaccine market, where interest in trials may be waning, potentially affecting future vaccine development and approval processes.
What's Next?
Moderna is also facing similar enrollment challenges in its COVID-19 vaccine trial for the same age group. The FDA's new requirements for placebo-controlled trials could further complicate the approval process for vaccines targeting older adults. The industry may need to explore alternative strategies to boost trial participation and address regulatory hurdles.
